New York, May 21, 2026, 10:04 (EDT)
- Pomdoctor’s Nasdaq-listed ADSs were last quoted at $0.1153 in early U.S. trading, down $0.0094 from the previous close.
- The stock was trading during regular Nasdaq hours; Nasdaq’s 2026 calendar lists Memorial Day, May 25, as the next U.S. market closure.
- The company remains in a Nasdaq minimum-bid cure period that runs to July 28.
Pomdoctor Limited’s U.S.-listed shares fell in early Nasdaq trading on Thursday, putting fresh focus on a Chinese digital-health microcap that is still trying to climb back above the exchange’s $1 minimum-bid threshold.
The American depositary shares, or ADSs — U.S.-traded receipts that represent foreign shares — were last quoted at $0.1153, down $0.0094 from the prior close, with volume at 172,520 shares. The intraday low was also $0.1153, according to market data.
Why it matters now is simple. Pomdoctor said in February that Nasdaq had notified it that its ADSs had closed below the $1 minimum bid price for 33 straight business days. Nasdaq gave the company until July 28 to regain compliance; to do that, the closing bid price — the price buyers are quoting — must be at least $1 for 10 consecutive business days.
The pressure comes a week after the Guangzhou-based company reported higher revenue but a much wider loss for 2025. Pomdoctor said net revenue rose 16.7% to RMB399.9 million, while net loss widened to RMB130.9 million from RMB37.4 million a year earlier. Gross margin, the share of sales left after direct costs, slipped to 13.1% from 13.9%.
Zhenyang Shi, Pomdoctor’s chairman and chief executive, called 2025 a year of “solid revenue expansion,” and said the company remained confident in China’s digital healthcare market. He also pointed to higher spending on research and development for artificial intelligence and healthcare-related applications. PR Newswire
The company’s Internet hospital business was the main growth driver. Revenue from that segment rose 69.3% to RMB150.7 million, helped by online pharmacy sales, while pharmaceutical supply-chain revenue fell 1.7% to RMB249.2 million. Pomdoctor also said two retail sales stores were closed because of high competition in retail pharmacy.
That leaves Pomdoctor fighting in a crowded China online-health market. JD Health’s business spans retail pharmacy and healthcare services, while Alibaba has described Alibaba Health as a flagship healthcare platform that should remain part of its consolidated group; both are larger reference points for investors looking at Chinese online pharmacy and digital-care models.
The broader tape was not much help. Wall Street’s main indexes opened lower on Thursday as oil jumped on renewed Middle East concerns, with the Nasdaq Composite down 0.48% at the opening bell, Reuters reported. Pomdoctor’s move was sharper than that early market decline.
But the risk is not only the day’s price action. Pomdoctor reported RMB148.5 million of net cash used in operating activities for 2025 and RMB9.6 million of cash and cash equivalents at year-end. If the ADSs fail to recover and hold the $1 bid by the July deadline, the key question becomes whether Nasdaq gives more time or the company has to take further steps to protect the listing.
Pomdoctor listed on the Nasdaq Global Market in October at $4 per ADS and raised gross proceeds of about $23 million after the underwriter fully exercised its over-allotment option. Thursday’s quote keeps the stock far below that IPO price, leaving investors to weigh revenue growth against losses, cash use and the listing clock.
